Advanced search
Publication Cover
Immunotherapy Volume 2, 2010 - Issue 6
Submit an article Journal homepage
852
Views
0
CrossRef citations to date
0
Altmetric
Review

Anti-TNF-α Agents in the Treatment of Immune-Mediated Inflammatory Diseases: Mechanisms of Action and Pitfalls

Léia CR Silva1 Laboratory of Dermatology & Immunodeficiencies, Dermatology Division, Clinics Hospital, São Paulo, Brazil
,
Luciena CM Ortigosa1 Laboratory of Dermatology & Immunodeficiencies, Dermatology Division, Clinics Hospital, São Paulo, Brazil
&
Gil Benard1 Laboratory of Dermatology & Immunodeficiencies, Dermatology Division, Clinics Hospital, São Paulo, Brazil;2 Laboratory of Medical Mycology, Tropical Medicine Institute, University of São Paulo Medical School, São Paulo, Brazil: R Dr Eneas de Carvalho Aguiar 470, Instituto de Medicina Tropical (IMT), Cerqueira Cesar, São Paulo, SP, 05403 903, Brazil. Tel.: +55 11 3061 7457 Fax: +55 11 3081 [email protected]
Pages 817-833 | Published online: 22 Nov 2010

Bibliography

  • Carswell EA , OldLJ, KasselRL et al.: An endotoxin-induced serum factor that causes necrosis of tumors.Proc. Natl Acad. Sci. USA72(9) , 3666–3670 (1975).
  • Bazzoni F , BeutlerB: The tumor necrosis factor ligand and receptor families.N. Engl. J. Med.334(26) , 1717–1725 (1996).
  • Kollias G , KontoyiannisD: Role of TNF/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatments.Cytokine Growth Factor Rev.13(4–5) , 315–321 (2002).
  • Pfeffer K : Biological functions of tumor necrosis factor cytokines and their receptors.Cytokine Growth Factor Rev.14(3–4) , 185–191 (2003).
  • Feldmann M , MainiRN: Discovery of TNF-α as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies.Joint Bone Spine69(1) , 12–18 (2002).
  • Knight DM , TrinhH, LeJ et al.: Construction and initial characterization of a mouse–human chimeric anti-TNF antibody.Mol. Immunol.30(16) , 1443–1453 (1993).
  • Tracey D , KlareskogL, SassoEH et al.: Tumor necrosis factor antagonist mechanisms of action: a comprehensive review.Pharmacol. Ther.117(2) , 244–279 (2008).
  • Remicade® (infliximab), prescribing information. Centocor, Inc., PA, USA (2006).
  • Wong M , ZiringD, KorinY et al.: TNF α blockade in human diseases: mechanisms and future directions.Clin. Immunol.126(2) , 121–136 (2007).
  • Enbrel® (etanercept), prescribing information. Immunex Corp., CA, USA (2007).
  • Humira (adalimumab), prescribing information. Abbott Laboratories, IL, USA (2007).
  • Sands BE : Why do anti-tumor necrosis factor antibodies work in Crohn‘s disease?Rev. Gastroenterol. Disord.4(Suppl. 3) , S10–S17 (2004).
  • Tak PP : Effects of infliximab treatment on rheumatoid synovial tissue.J. Rheumatol. Suppl.74 , 31–34 (2005).
  • Smeets TJ , KraanMC, van Loon ME et al.: Tumor necrosis factor α blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum.48(8) , 2155–2162 (2003).
  • Catrina AI , TrollmoC, af Klint E et al.: Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum.52(1) , 61–72 (2005).
  • Vigna-Pérez M , Abud-MendozaC, Portillo-SalazarH et al.: Immune effects of therapy with adalimumab in patients with rheumatoid arthritis.Clin. Exp. Immunol.141(2) , 372–380 (2005).
  • ten Hove T , van Montfrans C, Peppelenbosch MP et al.: Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn‘s disease. Gut50(2) , 206–211 (2002).
  • Di Sabatino A , CiccocioppoR, CinqueB et al.: Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn‘s disease.Gut53(1) , 70–77 (2004).
  • Lügering A , SchmidtM, LügeringN et al.: Infliximab induces apoptosis in monocytes from patients with chronic active Crohn‘s disease by using a caspase-dependent pathway.Gastroenterology121(5) , 1145–1157 (2001).
  • Goedkoop AY , KraanMC, PicavetDI et al.: Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study.Arthritis Res. Ther.6(4) , R326–R334 (2004).
  • Krüger-Krasagakis S , GalanopoulosVK, GiannikakiL et al.: Programmed cell death of keratinocytes in infliximab-treated plaque-type psoriasis.Br. J. Dermatol.154(3) , 460–466 (2006).
  • Malaviya R , SunY, TanJK et al.: Etanercept induces apoptosis of dermal dendritic cells in psoriatic plaques of responding patients.J. Am. Acad. Dermatol.55(4) , 590–597 (2006).
  • Malaviya R , SunY, TanJK et al.: Induction of lesional and circulating leukocyte apoptosis by infliximab in a patient with moderate to severe psoriasis.J. Drugs Dermatol.5(9) , 890–893 (2006).
  • Schottelius AJ , MoldawerLL, DinarelloCA et al.: Biology of tumor necrosis factor-α – implications for psoriasis.Exp. Dermatol.13(4) , 193–222 (2004).
  • Charles P , ElliottMJ, DavisD et al.: Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-α therapy in rheumatoid arthritis.J. Immunol.163(3) , 1521–1528 (1999).
  • Pittoni V , BombardieriM, SpinelliFR et al.: Anti-tumour necrosis factor (TNF) α treatment of rheumatoid arthritis (infliximab) selectively down regulates the production of interleukin (IL) 18 but not of IL12 and IL13.Ann. Rheum. Dis.61(8) , 723–725 (2002).
  • Ulfgren AK , AnderssonU, EngströmM et al.: Systemic anti-tumor necrosis factor α therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor α synthesis.Arthritis Rheum.43(11) , 2391–2396 (2000).
  • Schotte H , SchlüterB, WillekeP et al.: Long-term treatment with etanercept significantly reduces the number of proinflammatory cytokine-secreting peripheral blood mononuclear cells in patients with rheumatoid arthritis.Rheumatology (Oxford)43(8) , 960–964 (2004).
  • Zou J , RudwaleitM, BrandtJ et al.: Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab.Arthritis Rheum.48(3) , 780–790 (2003).
  • Zou J , RudwaleitM, BrandtJ et al.: Up regulation of the production of tumour necrosis factor α and interferon-γ by T cells in ankylosing spondylitis during treatment with etanercept.Ann. Rheum. Dis.62(6) , 561–564 (2003).
  • Rudwaleit M , SiegertS, YinZ et al.: Low T cell production of TNFα and IFNγ in ankylosing spondylitis: its relation to HLA-B27 and influence of the TNF-308 gene polymorphism.Ann. Rheum. Dis.60(1) , 36–42 (2001).
  • Rudwaleit M , AndermannB, AltenR et al.: Atopic disorders in ankylosing spondylitis and rheumatoid arthritis.Ann. Rheum. Dis.61(11) , 968–974 (2002).
  • Gottlieb AB , ChamianF, MasudS et al.: TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques.J. Immunol.175(4) , 2721–2729 (2005).
  • Taylor PC , PetersAM, PaleologE et al.: Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor α blockade in patients with rheumatoid arthritis.Arthritis Rheum.43(1) , 38–47 (2000).
  • van Deventer SJ : Tumour necrosis factor and Crohn‘s disease.Gut40(4) , 443–448 (1997).
  • Markham T , MullanR, Golden-MasonL et al.: Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy.J. Am. Acad. Dermatol.54(6) , 1003–1012 (2006).
  • Aggarwal A , PandaS, MisraR: Effect of etanercept on matrix metalloproteinases and angiogenic vascular endothelial growth factor: a time kinetic study.Ann. Rheum. Dis.63(7) , 891–892 (2004).
  • Cordiali-Fei P , TrentoE, D‘AgostoG et al.: Decreased levels of metalloproteinase-9 and angiogenic factors in skin lesions of patients with psoriatic arthritis after therapy with anti-TNF-α.J. Autoimmune Dis.3 , 5 (2006).
  • Curran S , MurrayGI: Matrix metalloproteinases in tumour invasion and metastasis.J. Pathol.189(3) , 300–308 (1999).
  • Maini RN , TaylorPC: Anti-cytokine therapy for rheumatoid arthritis.Ann. Rev. Med.51 , 207–229 (2000).
  • Firestein GS : Etiology and pathogenesis of rheumatoid arthritis. In: Textbook of Rheumatology (5th Edition). Kelley WN, Harris ED Jr, Ruddy S, Sledge CB (Eds). WB Saunders, PA, USA, 851–897 (1997).
  • Ishiguro N , ItoT, ObataK et al.: Determination of stromelysin-1, 72 and 92 kDa type IV collagenase, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-2 in synovial fluid and serum from patients with rheumatoid arthritis.J. Rheumatol.23 , 1599–1604 (1996).
  • Zucker S , LysikRM, ZarrabiMH et al.: Elevated plasma stromelysin levels in arthritis.J. Rheumatol.21 , 2329–2333 (1994).
  • Catrina AI , LampaJ, ErnestamS et al.: Anti-tumour necrosis factor (TNF)-α therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis.Rheumatology (Oxford)41(5) , 484–449 (2002).
  • Brennan FM , BrowneKA, GreenPA et al.: Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-α (cA2) therapy.Br. J. Rheumatol.36 , 643–650 (1997).
  • Kruithof E , De Rycke L, Roth J et al.: Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies. Arthritis Rheum.52(12) , 3898–3909 (2005).
  • Victor FC , GottliebAB, MenterA: Changing paradigms in dermatology: tumor necrosis factor α (TNFα) blockade in psoriasis and psoriatic arthritis.Clin. Dermatol.21 , 392–397 (2003).
  • Tak PP , TaylorPC, BreedveldFC et al.: Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor α monoclonal antibody treatment in patients with rheumatoid arthritis.Arthritis Rheum.39(7) , 1077–1081 (1996).
  • Paleolog EM , HuntM, ElliottMJ et al.: Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor α antibody in rheumatoid arthritis.Arthritis Rheum.39(7) , 1082–1091 (1996).
  • Klimiuk PA , SierakowskiS, DomyslawskaI et al.: Reduction of soluble adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor levels in serum of rheumatoid arthritis patients following multiple intravenous infusions of infliximab.Arch. Immunol. Ther. Exp. (Warsz).52(1) , 36–42 (2004).
  • Goedkoop AY , KraanMC, TeunissenMB et al.: Early effects of tumour necrosis factor α blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis.Ann. Rheum. Dis.63(7) , 769–773 (2004).
  • Miyara M , SakaguchiS: Natural regulatory T cells: mechanisms of suppression.Trends Mol. Med.13(3) , 108–116 (2007).
  • Lipsky PE , van der Heijde DMFM, St Clair EW et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med.343 , 1594–1602 (2000).
  • Valencia X , StephensG, Goldbach-ManskyR et al.: TNF downmodulates the function of human CD4+CD25hi T-regulatory cells.Blood108 , 253–261 (2006).
  • Ehrenstein MR , EvansJG, SinghA et al.: Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFα therapy.J. Exp. Med.200(3) , 277–285 (2004).
  • Nadkarni S , MauriC, EhrensteinMR: Anti-TNF-α therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-β.J. Exp. Med.204(1) , 33–39 (2007).
  • Scallon B , CaiA, SolowskiN et al.: Binding and functional comparisons of two types of tumor necrosis factor antagonists.J. Pharmacol. Exp. Ther.301 , 418–426 (2002).
  • Scallon BJ , MooreMA, TrinhH et al.: Ghrayeb, chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions.Cytokine7 , 251–259 (1995).
  • Gramlick A , FossatiG, NesbittAM et al.: Neutralization of soluble and membrane tumor necrosis factor-α (TNF-α) by infliximab, adalimumab, or certolizumab pegol using P55 or P75 TNF-α receptor-specific bioassays,Gastroenterology130(4) , A697 (2006).
  • Nesbitt AM , FossatiG, BrownDT: Comparison of certolizumab pegol, etanercept, adalimumab, and infliximab: effect on lipopolysaccharide-induced cytokine production by human peripheral blood monocytes.Am. J. Gastroenterol.101(Suppl. 2) , S420–S470 (2006).
  • Bruns H , MeinkenC, SchauenbergP, et al.: Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J. Clin. Invest.119(5) , 1167–1177 (2009).
  • Eissner G , KolchW, ScheurichP: Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system.Cytokine Growth Factor Rev.15 , 353–366 (2004).
  • Harashima SI , HoriuchiT, HattaN et al.: Outside-to-inside signal through the membrane TNF-α induces E-selectin (CD62E) expression on activated human CD4+ T cells.J. Immunol.166 , 130–136 (2001).
  • Mitoma H , HoriuchiT, HattaN et al.: Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-α.Gastroenterology128 , 376–392 (2005).
  • Nesbitt A , FossatiG, BerginM et al.: Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor α agents.Inflamm. Bowel Dis.13(11) , 1323–1332 (2007).
  • Kyle S , ChandlerD, GriffithsCE et al. Guideline for anti-TNF-α therapy in psoriatic arthritis. Rheumatology (Oxford) 44 , 390–397 (2005).
  • Sadowski DC , BernsteinCN, BittonA, CroitoruK, FedorakRN, Griffiths A; CAG Crohn‘s Consensus Group: Canadian Association of Gastroenterology Clinical Practice Guidelines: the use of tumour necrosis factor-α antagonist therapy in Crohn‘s disease. Can. J. Gastroenterol.23(3) , 185–202 (2009).
  • Fautrel B , PhamT, MouterdeG et al.: Recommendations of the French Society for Rheumatology regarding TNF-α antagonist therapy in patients with rheumatoid arthritis.Joint Bone Spine74(6) , 627–637 (2007).
  • Rogan MP , ThomasK: Fatal miliary coccidioidomycosis in a patient receiving infliximab therapy: a case report.J. Med. Case Reports1 , 79 (2007).
  • Inanc N , DireskeneliH: Serious infections under treatment with TNF-α antagonists compared to traditional DMARDs in patients with rheumatoid arthritis.Rheumatol. Int.27(1) , 67–71 (2006).
  • Toussirot E , StreitG, WendlingD: Infectious complications with anti-TNFα therapy in rheumatic diseases: a review.Recent Pat. Inflamm. Allergy Drug Discov.1(1) , 39–47 (2007).
  • Haroon M , BondU, PhelanM: Sinusitis: a possible link with adalimumab.Clin. Rheumatol.27(9) , 1189–1190 (2008).
  • Estrada S , García-CamposF, CalderónR, DelgadoE, BengoaR, EncisoC: Pneumocystis jiroveci(carinii) pneumonia following a second infusion of infliximab in a patient with ulcerative colitis.Inflamm. Bowel Dis.15(2) , 315–316 (2009).
  • Komano Y , HarigaiM, KoikeR et al.: Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case–control study of 21 patients.Arthritis Rheum.61(3) , 305–312 (2009).
  • Elbek O , UyarM, AydinN et al.: Increased risk of tuberculosis in patients treated with antitumor necrosis factor-α.Clin. Rheumatol.28(4) , 421–426 (2009).
  • Endean AL , BarrySM, Young-MinSA: Possible miliary tuberculosis during adalimumab therapy with negative γ-IFN release assays.Rheumatology (Oxford)48(3) , 319–320 (2009).
  • Antolín J , AzaharaM, HernándezC, BlancoM, MaoL, CigüenzaR: Tuberculous peritonitis after treatment with adalimumab.Scand. J. Infect. Dis.40(8) , 677–678 (2008).
  • Galati V , GrilliE, Busi Rizzi E, Prantera C, Petrosillo N: Cerebral tubercular lesions in a patient treated with infliximab for Crohn‘s disease. J. Neurol.255(12) , 1981–1982 (2008).
  • Malkin J , ShrimptonA, WiselkaM, BarerMR, DuddridgeM, PereraN: Olecranon bursitis secondary to Mycobacterium kansasii infection in a patient receiving infliximab for Behcet‘s disease.J. Med. Microbiol.58(Pt 3) , 371–373 (2009).
  • Martín-Aspas A , Guerrero-SánchezF, García-MartosP, González-MoyaE, Medina-VaroF, Girón González JÁ: Bilateral pneumonia by Mycobacterium aurum in a patient receiving infliximab therapy. J. Infect.57(2) , 167–169 (2008).
  • Micekova D , SolovicI, RovenskyJ et al.: Effectiveness of the combination of a whole-blood interferon-γ assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy.Arthritis Rheum.59(6) , 800–806 (2008).
  • Fernández-Guerrero ML , EstebanJ, AcebesC, GórgolasM: Failure of isoniazid chemoprophylaxis during infliximab therapy.Emerg. Infect. Dis.13(9) , 1428–1429 (2007).
  • Ledingham J , DeightonC: Update on the British Society for Rheumatology guidelines for prescribing TNF-α blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001).Rheumatology (Oxford)45(6) , 649–652 (2006).
  • Oberstein EM , KromoO, TozmanEC: Type I reaction of Hansen‘s disease with exposure to adalimumab: a case report.Arthritis Rheum.59(7) , 1040–1043 (2008).
  • Narayana N , GiffordR, GianniniP, CaseyJ: Oral histoplasmosis: an unusual presentation.Head Neck31(2) , 274–277 (2009).
  • Manz M , BeglingerC, VavrickaSR: Fatal invasive pulmonary aspergillosis associated with adalimumab therapy.Gut58(1) , 149 (2009); comment on: Gut56(9) , 1232–1239 (2007).
  • Galandiuk S , DavisBR: Infliximab-induced disseminated histoplasmosis in a patient with Crohn‘s disease.Nat. Clin. Pract. Gastroenterol. Hepatol.5(5) , 283–287 (2008).
  • Kozic H , RiggsK, RingpfeilF, LeeJB: Disseminated Cryptococcus neoformans after treatment with infliximab for rheumatoid arthritis.J. Am. Acad. Dermatol.58(5 Suppl. 1) , S95–S96 (2008).
  • Odessey E , CohnA, BeamanK, SchechterL: Invasive mucormycosis of the maxillary sinus: extensive destruction with an indolent presentation.Surg. Infect.9(1) , 91–98 (2008).
  • Saad AA , SymmonsDP, NoycePR, AshcroftDM: Risks and benefits of tumor necrosis factor-α inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials.J. Rheumatol.35(5) , 883–890 (2008).
  • Tektonidou MG , SkopouliFN: Visceral leishmaniasis in a patient with psoriatic arthritis treated with infliximab: reactivation of a latent infection?Clin. Rheumatol.27(4) , 541–542 (2008).
  • Pizzorni C , SecchiME, CutoloM: [Leishmaniasis in rheumatoid arthritis.]Reumatismo59(3) , 235–239 (2007).
  • Bongartz T , SuttonAJ, SweetingMJ, BuchanI, MattesonEL, MontoriV: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.JAMA295(19) , 2275–2285 (2006).
  • Wölbing F , FierlbeckG, HötzeneckerW, SchallerM, RöckenM: Septic shock after treatment of Pyoderma gangrenosum with infliximab.Acta Derm. Venereol.89(1) , 93–94 (2009).
  • Benítez-Macías JF , García-GilD, Brun-RomeroFM: [Fatal phenmococcal sepsis in patient with hidradenitis suppurative treated with inflixumeb.]Med. Clin. (Barc.)131(20) , 799 (2008).
  • Choi KH , YooWH: Necrotizing fasciitis in a patient treated with etanercept for dermatomyositis.Rheumatol. Int.29(4) , 463–466 (2009).
  • Darabi K , JaiswalR, HostetlerS, BechtelM, ZirwasM: Infectious complications in patients with psoriasis and rheumatoid arthritis treated with antitumor necrosis factor agents and methotrexate.J. Drugs Dermatol.8(2) , 175–178 (2009).
  • Williams G , KhanAA, SchweigerF: Listeria meningitis complicating infliximab treatment for Crohn‘s disease.Can. J. Infect. Dis. Med. Microbiol.16(5) , 289–292 (2005).
  • Peyrin-Biroulet L , DeltenreP, de Suray N, Branche J, Sandborn WJ, Colombel JF: Efficacy and safety of tumor necrosis factor antagonists in Crohn‘s disease: meta-analysis of placebo-controlled trials. Clin. Gastroenterol. Hepatol.6(6) , 644–653 (2008).
  • Nobile S , CatassiC, FeliciL: Herpes zoster infection followed by Henoch–Schönlein purpura in a girl receiving infliximab for ulcerative colitis.J. Clin. Rheumatol.15(2) , 101 (2009); comment on: J. Clin. Rheumatol.12(5) , 249–251 (2006).
  • Strangfeld A , ListingJ, HerzerP et al.: Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-α agents.JAMA301(7) , 737–744 (2009); comment on: JAMA301(7) , 774–775 (2009).
  • Wendling D , StreitG, ToussirotE, PratiC: Herpes zoster in patients taking TNF-α antagonists for chronic inflammatory joint disease.Joint Bone Spine75(5) , 540–543 (2008).
  • Domm S , CinatlJ, MrowietzU: The impact of treatment with tumour necrosis factor-α antagonists on the course of chronic viral infections: a review of the literature.Br. J. Dermatol.159(6) , 1217–1228 (2008).
  • Becart S , SegaertS: Recurrent varicella in an adult psoriasis patient treated with etanercept.Dermatology217(3) , 260–261 (2008).
  • Justice EA , KhanSY, LoganS, JobanputraP: Disseminated cutaneous herpes simplex virus-1 in a woman with rheumatoid arthritis receiving INFLIXIMAB: a case report.J. Med. Case Reports2 , 282 (2008).
  • Komatsuda A , WakuiH, NimuraT, SawadaK: Reversible infliximab-related lymphoproliferative disorder associated with Epstein–Barr virus in a patient with rheumatoid arthritis.Mod. Rheumatol.18(3) , 315–318 (2008).
  • Ojiro K , NaganumaM, EbinumaH et al.: Reactivation of hepatitis B in a patient with Crohn‘s disease treated using infliximab.J. Gastroenterol.43(5) , 397–401 (2008).
  • Favalli EG , DesiatiF, AtzeniF et al.: Serious infections during anti-TNFα treatment in rheumatoid arthritis patients.Autoimmun. Rev.8(3) , 266–273 (2009).
  • Menter A , ReichK, GottliebAB et al.: Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations.J. Drugs Dermatol.7(12) , 1137–1146 (2008).
  • Callen JP : Immunomodulators. In: Dermatology (2nd Edition). Bologna J, Jorizzo JL, Rapini RP (Eds). Mosby, UK 1973–1990 (2008).
  • Eitstrom Smedby K , VajdicCM, FalsterM et al.: Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the Interlymph Consortium.Blood111(8) , 4029–4038 (2008).
  • de Vries HS , van Oijen MG, de Jong DJ: Serious events with infliximab in patients with inflammatory bowel disease: a 9 year cohort study in The Netherlands. Drug Saf.31(12) , 1135–1144 (2008).
  • Mackey AC , GreenL, LeptakC, AviganM: Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update.J. Pediatr. Gastroenterol. Nutr.48(3) , 386–388 (2009); comment on: J. Pediatr. Gastroenterol. Nutr.44(2) , 265–267 (2007).
  • Ganguly S : Leukemic phase of follicular lymphoma after treatment with etanercept in a patient with psoriasis.Am. J. Clin. Dermatol.10(2) , 125–126 (2009).
  • Comte C , GuilhouJJ, GuillotB, DereureO: Rapid onset and fatal outcome of two squamous cell carcinomas of the genitalia in a patient treated with etanercept for cutaneous psoriasis.Dermatology217(3) , 284–285 (2008).
  • Chuang GS , WassermanDI, ByersHR, DemierreMF: Hypopigmented T-cell dyscrasia evolving to hypopigmented mycosis fungoides during etanercept therapy.J. Am. Acad. Dermatol.59(Suppl. 5) , S121–S122 (2008).
  • Hurley MY , GeorgeMN, LeonardiCL, FraterJL: A transient benign lymph node-based proliferation of T-cells simulating non-Hodgkin lymphoma in a patient with psoriasis treated with tumor necrosis factor α and CD11a antagonists.Diagn. Pathol.3 , 13 (2008).
  • Aksu K , DonmezA, ErtanY et al.: Hodgkin‘s lymphoma following treatment with etanercept in ankylosing spondylitis.Rheumatol. Int.28(2) , 185–187 (2007).
  • Weimer LH , SachdevN: Update on medication-induced peripheral neuropathy.Curr. Neurol. Neurosci. Rep.9(1) , 69–75 (2009).
  • Makol A , GroverM: Adalimumab induced mononeuritis multiplex in a patient with refractory rheumatoid arthritis: a case report.Cases J.1(1) , 287 (2008).
  • Zamvar V , SugarmanID, TawfikRF, Macmullen-PriceJ, PuntisJW: Posterior reversible encephalopathy syndrome following infliximab infusion.J. Pediatr. Gastroenterol. Nutr.48(1) , 102–105 (2009).
  • Kameda T , DobashiH, KittakaK et al.: A case of rheumatoid arthritis complicated by demyelination in both cerebral cortex and spinal cord during etanercept therapy.Mod. Rheumatol.18(4) , 399–402 (2008).
  • Booker MJ , FlintJ, SaravanaS: Aseptic meningitis in a patient taking etanercept for rheumatoid arthritis: a case report.Cases J.1(1) , 364 (2008).
  • Hooper DR , TarnopolskyMA, BakerSK: Lewis–Sumner syndrome associated with infliximab therapy in rheumatoid arthritis.Muscle Nerve38(4) , 1318–1325 (2008).
  • Russo MA , DorahyDJ: Complex regional pain syndrome after infliximab infusion.J. Pain Symptom Manage.37(3) , E9–E10 (2009); comment on: J. Pain Symptom Manage.36(3) , E2–E4 (2008).
  • Stübgen JP : Tumor necrosis factor-α antagonists and neuropathy.Muscle Nerve37(3) , 281–292 (2008).
  • Pfueller CF , SeipeltE, ZippF, PaulF: Multiple sclerosis following etanercept treatment for ankylosing spondylitis.Scand. J. Rheumatol.37(5) , 397–399 (2008).
  • Gonnet-Gracia C , BarnetcheT, RichezC, BlancoP, DehaisJ, SchaeverbekeT: Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-α blockers.Clin. Exp. Rheumatol.26(3) , 401–407 (2008).
  • Martín JM , RicartJM, AlcácerJ, RausellN, AranaG: Adalimumab-induced lupus erythematosus.Lupus17(7) , 676–678 (2008).
  • Mounach A , GhaziM, NouijaiA et al.: Drug-induced lupus-like syndrome in ankylosing spondylitis treated with infliximab.Clin. Exp. Rheumatol.26(6) , 1116–1118 (2008).
  • Benucci M , NenciG, CappellettiC, ManfrediM: Lupus like syndrome induced by treatment with anti TNFα (infliximab): report of three cases.Recenti. Prog. Med.99(7–8) , 363–366 (2008).
  • Cuchacovich R , EspinozaCG, VirkZ, EspinozaLR: Biologic therapy (TNF-α antagonists)-induced psoriasis: a cytokine imbalance between TNF-α and IFN-α?J. Clin. Rheumatol.14(6) , 353–356 (2008).
  • Chan CY , BrowningJC, LarsenF, HsuS: Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis.Dermatol. Online J.14(9) , 12 (2008).
  • Costa-Romero M , Coto-SeguraP, Suarez-SaavedraS, Ramos-PoloE, Santos-JuanesJ: Guttate psoriasis induced by infliximab in a child with Crohn‘s disease.Inflamm. Bowel Dis.14(10) , 1462–1463 (2008).
  • Monteagudo Sánchez B , CabanillasM, Ortiz-S, Gallego-OjeaJC: [Infliximab-induced pustular psoriasis in a patient with Crohn‘s disease.]Gastroenterol. Hepatol.32(3) , 175–176 (2009).
  • Wermuth J , KindF, SteuerwaldM: Palmoplantar pustulosis and acrodermatitis in a patient treated with infliximab for Crohn‘s sacroiliitis.Clin. Gastroenterol. Hepatol.7(2) , A28 (2009).
  • Harris MD , RichardsR: First case report of adalimumab-induced psoriasis in Crohn‘s disease.Am. J. Gastroenterol.104(3) , 792–793 (2009).
  • Richetta A , MattozziC, CarlomagnoV et al.: A case of infliximab-induced psoriasis.Dermatol. Online J.14(11) , 9 (2008).
  • Harrison MJ , DixonWG, WatsonKD et al.: Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register.Ann. Rheum. Dis.68(2) , 209–215 (2009).
  • Collamer AN , GuerreroKT, HenningJS, BattafaranoDF: Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action.Arthritis Rheum.59(7) , 996–1001 (2008).
  • Levine SD , RobinsonM, HondaK, NedorostS: Interstitial granulomatous dermatitis in a patient with rheumatoid arthritis on etanercept.Cutis83(1) , 50 (2009).
  • Deng A , HarveyV, SinaB et al.: Intersticial granulomatous dermatitis associated with the use of tumor necrosis factor-α inhibitors.Arch. Dermatol.142 , 198–202 (2006).
  • Roé E , PuigL, CorellaF, García-NavarroX, AlomarA: Cutaneous adverse effects of biological therapies for psoriasis.Eur. J. Dermatol.18(6) , 693–699 (2008).
  • Mangat P , WhittleS, ClelandL: Digital vasculitis: a late complication of anti-tumour necrosis factor α therapy.Clin. Rheumatol.27(12) , 1593–1595 (2008).
  • Lahbabi I , AdamskiH, Le Jean S, Cannieux V, Polard E, Chevrant-Breton J: Neutropenia and thrombocytopenia in a patient presenting psoriasis treated with etanercept. Ann. Dermatol. Venereol.135(5) , 409–410 (2008).
  • de Oliveira JP , LevyA, MorelP, GuibalF: Severe neutrophilia induced by infliximab for psoriasis.Br. J. Dermatol.158(1) , 200–201 (2008).
  • Hatakeyama T , KomatsudaA, MatsudaA et al.: Renal amyloidosis associated with extracapillary glomerulonephritis and vasculitis in a patient with inflammatory bowel disease treated with infliximab.Clin. Nephrol.70(3) , 240–244 (2008).
  • Portuesi MG , PerosaP: Neprhrotic syndrome in a patient with rheumatoid arthritis treated with adalimumab: a case report.Reumatismo60(1) , 61–63 (2008).
  • Leak AM , Rincon-AznarB: Hepatotoxicity associated with etanercept in psoriatic arthritis.J. Rheumatol.35(11) , 2286–2287 (2008).
  • Fathalla BM , GoldsmithDP, PascasioJM, BaldridgeA: Development of autoimmune hepatitis in a child with systemic-onset juvenile idiopathic arthritis during therapy with etanercept.J. Clin. Rheumatol.14(5) , 297–298 (2008).
  • García Simon MS , Saliente Callén S, López Avila A, Rabell Iñigo S: [Hepatic cytolysis from infliximab.] Farm. Hosp.32(4) , 250–252 (2008).
  • Yazisiz V , AvciAB, ErbasanF, YildirimB, TerziogluE: Development of Crohn‘s disease following anti-tumour necrosis factor therapy (etanercept).Colorectal Dis.10(9) , 953–954 (2008).
  • Lazzerini PE , AcampaM, HammoudM et al.: Arrhythmic risk during acute infusion of infliximab: a prospective, single-blind, placebo-controlled, crossover study in patients with chronic arthritis.J. Rheumatol.35(10) , 1958–1965 (2008).
  • Nishida K , OkadaY, NawataM, SaitoK, TanakaY: Induction of hyperadiponectinemia following long-term treatment of patients with rheumatoid arthritis with infliximab (IFX), an anti-TNF-α antibody.Endocr. J.55(1) , 213–216 (2008).
  • Burke JP , KelleherB, RamadanS, QuinlanM, SugrueD, O‘DonovanMA: Pericarditis as a complication of infliximab therapy in Crohn‘s disease.Inflamm. Bowel Dis.14(3) , 428–429 (2008).
  • Díez Piña JM , Vázquez Gómez O, Mayoralas Alises S, García Jiménez JD, Alvaro Alvarez D, Rodríguez Bolado MP: Etanercept as a possible trigger of fatal pulmonary fibrosis. Arch. Bronconeumol.44(7) , 393–395 (2008).
  • Janssen R , KrivokucaI, KruizeAA, KoendermanL, LammersJW: Adalimumab-induced bronchospasm: not a class effect.Thorax63(5) , 472–473 (2008).
  • Hejazi R , ColombelJF, Peyrin-BirouletL: Retrobulbar optic neuritis during infliximab treatment for ulcerative colitis.Gastroenterol. Clin. Biol.32(2) , 162–163 (2008).
  • Veerappan SG , KennedyM, O‘MorainCA, RyanBM: Retinal vein thrombosis following infliximab treatment for severe left-sided ulcerative colitis.Eur. J. Gastroenterol. Hepatol.20(6) , 588–589 (2008).
  • Stinco G , PiccirilloF, PatroneP: Hypertriglyceridaemia during treatment with adalimumab in psoriatic arthritis.Br. J. Dermatol.157(6) , 1273–1274 (2007).
  • Dryden GW : Overview of biologic therapy for Crohn‘s diseas.Expert Opin. Biol. Ther.9(8) , 967–974 (2009).
  • Menter A : The status of biologic therapies in the treatment of moderate to severe psoriasis.Cutis84(Suppl. 4) , 14–24 (2009).
  • Arnauld L , HarocheJ, PietteJC, AmouraZ: [The immunomodulatory biotherapies of the future: what perspectives?].Presse Med.38 , 749–760 (2009).
  • Ohno S , NakamuraS, HoriS et al.: Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet disease with refractory uveoretinitis.J. Rheumatol.31 , 1362–1368 (2004).
  • Yamada Y , SugitaS, TanakaH, KamoiK, KawaguchiT, MochizukiM: Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease.Br. J. Ophthalmol.94(3) , 284–288 (2010).
  • Sitapati AM , KaoCL, CachayER et al.: Treatment of HIV-related inflammatory cerebral cryptococcoma with adalimumab.Clin. Infect. Dis.50 , E7–E10 (2010).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.